ReviewDrugs2023
Zuranolone: First Approval.
Review in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis.Psychopharmacology · 2024Pooled it
- Caregivers' knowledge, attitudes, and practices regarding postpartum depression: a cross-sectional study.Scientific reports · 2026Article
- A systematic safety assessment of zuranolone: real-world adverse event analysis from the FAERS database.Archives of women's mental health · 2026Article
- Examining New Mothers' Access to Zuranolone.Ochsner journal · 2026Article
- Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.Drug design, development and therapy · 2026Review
- Pharmacological Insights on USFDA-approved Novel Drug Therapies in the Year 2023.Current drug discovery technologies · 2026Review
- Rotamer-Controlled Self-Immolative Linkers Enable Tunable Release of Neurosteroid Oxime Prodrugs.ACS medicinal chemistry letters · 2025Article
- Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression.European archives of psychiatry and clinical neuroscience · 2025Review
- Neuroactive Steroids as Novel Promising Drugs in Therapy of Postpartum Depression-Focus on Zuranolone.International journal of molecular sciences · 2025Review
- Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.Current obesity reports · 2025Review
- Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system.Frontiers in psychiatry · 2025Article
- Current Developments in the Treatment of Postpartum Depression: Zuranolone.The Eurasian journal of medicine · 2024Article
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zuranolone (ZURZUVAE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.